Editas Medicine Inc (NAS:EDIT)
$ 5.3 -0.13 (-2.39%) Market Cap: 435.86 Mil Enterprise Value: 173.83 Mil PE Ratio: 0 PB Ratio: 1.48 GF Score: 52/100

Editas Medicine Inc at Wells Fargo Healthcare Conference Transcript

Sep 07, 2023 / 07:00PM GMT
Release Date Price: $8.91 (-2.30%)
Yanan Zhu
Wells Fargo Securities - Analyst

Great. Thanks everyone for being here. My name is Yanan Zhu, and I'm one of the biotech analysts here at Wells Fargo. It's our privilege to have Editas Medicine's management team with us for our fireside chat here today.

With me here are Gilmore O'Neill, Chief Executive Officer; and Baisong Mei, Chief Medical Officer. Thank you, Baisong. Thank you, Gilmore, for being here.

Gilmore O;Neill
Editas Medicine, Inc. - President & CEO

' -

Thank you very much for having us.

Baisong Mei
Editas Medicine, Inc. - SVP & Chief Medical Officer

Thank you.

Questions & Answers

Yanan Zhu;Gilmore O
Wells Fargo Securities - Analyst

Great. So, I think -- if we could, let's dive right into EDIT-301 for sickle cell disease and the ongoing RUBY trial, if that's okay. Wondering, how many sites have been opened? How many patients have been enrolled? And how many have been dosed?

'

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot